Background Access to medications for opioid use disorder (MOUD) among racial/ethnic
minorities is a growing concern. Objectives Inequalities in receiving MOUD among gender …

Many patients with opioid use disorder (OUD) do not receive medication for opioid use
disorder (MOUD), including methadone, buprenorphine, or extended-release naltrexone. 1 …

Importance Little is known about the potential implications of the rapid transition to telehealth
during the COVID-19 pandemic for treatment of opioid use disorder (OUD). Objective To …

Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and
mortality from addiction, overdose, and related medical conditions. Despite our increasing …

Methods| The study was conducted between January and February 2023 and involved
internal medicine senior residents and attending physicians. The HPIs were generated by a …

Importance Few primary care (PC) practices treat patients with medications for opioid use
disorder (OUD) despite availability of effective treatments. Objective To assess whether …

The Opioid use disorder (OUD) is a growing concern in the workplace, with increasing
numbers of employees affected by this condition. OUD can have a significant impact on …

Importance Buprenorphine is underutilized as a treatment for opioid use disorder (OUD);
state policies may improve buprenorphine access and utilization. Objective To assess …

BACKGROUND AND OBJECTIVES Opioid related overdose among adolescents and young
adults in the United States is rising. Medications for opioid use disorder (MOUD), including …

Understanding drug market dynamics and their underlying driving factors is paramount to
developing effective responses to the overdose crisis in North America. This paper …